News
Making a Difference – The Broad Institute
In the Making a Difference series, KCCure’s Director of Patient Engagement, Laura Loughlin will be highlighting organizations making a difference in Kidney Cancer research. In this first article, we’re profiling work being done at the Broad Institute researching rare kidney cancer. The Broad Institute of Cambridge and Harvard Located in Cambridge, MA the Broad is a non-profit research organization partnered with MIT, Harvard and the five Harvard teaching hospitals. On October 18th I had the opportunity to visit the Broad. I attended a Pre-Launch Workshop for the Rare Cancer Dependency Map Initiative. This initiative provides a patient driven research platform seeking treatments for rare kidney cancers. The research starts with patients’ authorizing donation of fresh tissue...
Treatment for Metastatic Kidney Cancer Edges Toward Approval
AVEO Oncology announced today that the Phase 3 TIVO-3 Trial of Tivozanib in metastatic kidney cancer has met its primary endpoint.
Gene Therapy – An RCC Clinical Trial at the NIH
KCCure highlights new and exciting research in kidney cancer at the NIH as well as an RCC clinical trial that is open now for kidney cancer patients.
ESMO18 – Kidney Cancer Updates
KCCure reports live from #ESMO18 on kidney cancer updates and what we learned from the experts.
Lawing to Present on Rare Kidney Cancer at AACR Conference
Michael B. Lawing, Director of Outreach, KCCure has been selected to participate in the Scientist <-> Survivor Program at the 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved Nov. 2-5, 2018 in New Orleans, LA. The conference will address all levels of basic, population, clinical, and transdisciplinary research related to cancer and will bring together physicians, scientists, health professionals, and health care leaders working in a variety of disciplines to discuss the latest findings in their fields. Patient Advocates attending the meeting will communicate to scientists the key issues, questions, and concerns of the survivor and patient advocacy communities; and network with scientists and fellow advocates fr...
Letter to Kidney Cancer Journal and Response – Regarding Checkpoint Inhibitors in Non-Clear Cell RCC
Attached is a letter to the editor of the Kidney Cancer Journal and editorial response regarding the use of checkpoint inhibitors in non-clear cell RCC. We’re grateful to the editors of the journal for graciously providing this update for patients with rare types of kidney cancer. KCJ letter
KCCure urges Congress and CMS to Reconsider Misguided Medicare Changes
KCCure joins 239 advocacy organizations asking Congress and CMS to reconsider changes allowing Medicare Advantage plans to implement a new policy that could negatively impact Medicare patients with kidney cancer.
Deadline Extension for Federal Kidney Cancer Research Program
This is to notify the research community of the recently extended deadline for the Fiscal Year 2018 (FY18) funding opportunities for the Department of Defense (DOD) Kidney Cancer Research Program (KCRP) being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).
11th Annual Dana Farber/Harvard Cancer Center Kidney Cancer Symposium
On September 7th, the Harvard Medical Research Centers including Dana Farber, Beth Isreal, Brigham & Women's will once again hold their annual Kidney Cancer Symposium at the Newton Massachessetts Marriott. The Symposium is an all-day in-person and virtual event beginning at 8:00 a.m. and concluding at 3:30 pm.
We Hit our Goal! $50,000 in new Research Funding for Kidney Cancer
KCCure hits goal of raising $50,000 in new kidney cancer research funding. Learn more about our Kidney Cancer Research Grant Program and our mission for find a cure for kidney cancer.
Joe Paterniti – In Memoriam
KCCure tribute to Joe Paterniti (1969-2017) a dedicated father and husband who lost his life to kidney cancer.
KCCure Urges EMA to approve Opdivo/Yervoy for European Kidney Cancer Patients
July 30, 2018 Washington, DC, – The Kidney Cancer Research Alliance(KCCure) responded to the Committee for Medicinal Products for Human Use (CHMP) recommendation against approval by the European Medicines Agency (EMA) of ipilimumab (Yervoy) combined with nivolumab (Opdivo) for the first line treatment of high and intermediate risk metastatic renal cell carcinoma (kidney cancer). The question of single-agent versus combination therapy is relevant in kidney cancer today and we agree with CHMP that additional data showing the superiority of adding ipilimumab to nivolumab would benefit the field and broaden our understanding of how these agents work in kidney cancer. However, we don’t believe this question alone is sufficient enough to justify denying kidney cancer patients access to a treatme...